Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

NCT03782532 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03782532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03782532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 25, 2019
Completion date
May 21, 2022
Enrollment
486 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

asthma